Aug 18, 2016:
July 30, 2016:
Congratulations to Dr. Bibo Li for receiving a three-year collaborative (with Carnegie Mellon University/Dr. Kausik Chakrabarti) NSF grant award totaling $810,000. The grant is entitled "Collaborative Research: Telomerase Regulation in Deep Branching Eukaryotes". Dr. Li/CSU is awarded a total of $295,000. This project will examine telomerase function in the early lineage of eukaryotic evolution.
June 24, 2016:
June 19, 2016:
The National Institute of Allergy and Infectious Diseases (NIH) awards an AREA (R15) grant (second in a row) in the total amount of $436,500 to Dr. Bin Su for his research on discovery and development of novel antiprotozoal drugs. The title of the grant is “Selective tubulin inhibitors with improved cell update for kinetoplastid infections.” The proposed research will help create novel drugs for treatment of trypanosomiasis, also known as sleeping sickness, a widespread tropical disease, caused by protozoan parasites belonging to the genus Trypanosoma. This grant involves extensive collaboration with Dr. Bibo Li. Congratulations, Bin and Bibo!
June 18, 2016:
The National Institute of Allergy and Infectious Diseases (NIH) awards a grant in the total amount of $2,182,500 to Dr. Bibo Li for her research on antigenic variation/variant surface glycoprotein (VSG) switching in Trypanosoma brucei. Dr. Li has been holding her R01 grant since January 1, 2007 and renews it second time for the third consecutive term. The title of Dr. Li’s project is “Mechanisms of RAP1 functions in monoallelic VSG expression in Trypanosoma brucei”. Dr. Li’s research is devoted to the study of telomere function in the protozoan parasite T. brucei. T. brucei undergoes antigenic variation and regularly switches its major surface antigen, variant surface glycoprotein (VSG), to evade the host's immune attack. Telomeres, being adjacent to the expression sites of VSGs, have been shown to play an important role in VSG expression regulation. Dr. Li found that telomeric silencing and VSG switching in T. brucei depend on telomere protein RAP1. Dr. Li is a recipient of the College of Science Outstanding Research Award (2009). Over the past 9 years Dr. Li has brought more than $5M in NIH funding to CSU. Congratulations, Bibo!
June 16, 2016:
two best abstracts in the Clinical Diagnostic Immunology Division (CDID) of AACC. The 2016 AACC annual meeting will be held in Philadelphia, PA, July 31 - August 4. Katie is a graduate (PhD) student in Dr. Michael Kalafatis's lab. The title of her presentation is "Quantification of Death Receptors as Tumor Markers for the Prediction of TRAIL Sensitivity by Flow Cytometry". AACC Annual Scientific Meeting & Clinical Lab Expo is the leading event for laboratory medicine worldwide, where breakthrough innovations in clinical testing and patient care are introduced to the healthcare world. Congratulations, Katie and Michael!
May 20, 2016:
A groundbreaking study devoted to the mechanism of maintainance of Ca2+ homeostasis in the endoplasmic reticulum (ER) has been published in the journal Cell by Dr. Aimin Zhou and his colleagues from the Chinese Academy of Sciences. Maintaining of Ca2+ homeostasis is crucial for proper Ca2+ signaling, which impinges on many key cellular processes such as contraction, secretion, memory formation, gene transcription, cell growth, and cell death. The endoplasmic reticulum is the main intracellular Ca2+ store. Stimulation of cells with a variety of physiological stimuli leads to Ca2+ release from ER and the depletion of Ca2+ stores that have to be refilled for proper cellular function. The general mechanism of such refill was known, however it was unclear, if there is a mechanism for ER to extrude the excess Ca2+ when the store gets overloaded. The authors uncovered the function of the transmembrane and coiled-coil domains 1 (TMCO1) protein and showed that it is responsible for protecting Ca2+ stores from Ca2+ overload. Mutations in TMCO1 gene are known to be associated with TMCO1-defect syndrome, which is commonly leading to distinctive craniofacial dysmorphism, skeletal anomalies, mental retardation, ataxia, and many other clinical symptoms. This novel finding allowed to explain the origin of these defects. This study may potentially also help development of new therapies for TMCO1-defect syndrome treatment.
Cell is the leading journal in biology and the highest-impact journal in the world. Cell publishes findings of unusual significance in any area of experimental biology, including but not limited to cell biology, molecular biology, neuroscience, immunology, virology and microbiology, cancer, human genetics, systems biology, signaling, and disease mechanisms and therapeutics. Congratulations, Aimin!
May 19, 2016:
Dr. Anton A. Komar's and his colleagues recent Molecular Cell paper has been featured by the Human Frontier Science Program (HFSP) in the Frontier Science section, which presents information by and about HFSP awardees as well as topics of interest to scientists throughout the world working at the frontiers of the life sciences. The study published by Dr. Komar and his colleagues was supported by the HFSP Program grant.
May 18, 2016:
Dr. Andy Resnick's research on the biological function of sensory cilia that controls cell and tissue responses to applied fluid motion has been featured in a recent video pruduced by the Office of Research. Congratulations, Andy! Previously, Drs. Bibo Li's, Roman Kondratov's and Girish Shukla's studies have been featured in the CSU's Office of Research video Series.
May 18, 2016:
Dr. Bin Su received additional funding in the total amount of $240,000 for his project "Targeting EphA2 in Glioblastoma," which is an ongoing collaboration with Dr. Bingcheng Wang in the Case Western Reserve University School of Medicine. The project is funded by the National Institute of Neurological Disorders and Stroke (R01 grant) via CWRU. Congratulations, Bin!
May 14, 2016:
Rima Sandhu a graduate (PhD) student in Dr. Valentin Boerner's lab has been selected to give a platform presentation at the Meiosis Gordon Research Seminar (GRS) "Mechanisms of Sexual Reproduction Through Meiosis" to be held in New London, NH (June 25-26). The title of her presentation is "Processing of Stalled Meiotic Recombination Intermediates by a Newly Identified Chromosomal Protein". This GRS will be held in conjunction with the "Meiosis" Gordon Research Conference (GRC). For over 75 years, GRC's meetings have been recognized as the world's premier scientific conferences. Congratulations, Rima and Valentin!
May 14, 2016:
Dr. Anthony Berdis was selected to give a platform presentation at "The Controlling the Cancer Summit 2016" to be held in London, UK (May 17-19th). The title of Dr. Berdis's presentation is "Non-Natural Nucleosides as Therapeutic Agents Against Glioblastoma". The annual Controlling Cancer Summit is an international academic event attended by clinicians, academics and members of the pharmaceutical industry, representing a wide spectrum of cancer research, development and healthcare professionals. Congratulations, Tony!
May 02, 2016:
Apr 20, 2016:
Vice President for Research Dr. Jerzy Sawicki and Interim Provost and Senior Vice President for Academic Affairs Dr. Jianping Zhu have reviewed and approved GRHD External Advisory Committee's recommendation/proposal for elevating the Center for Gene Regulation in Health and Disease (GRHD) status from Type 3 to a Type 4 University Research Center (the highest at CSU). This provides the infrastructure support functions needed by a group of faculty with shared education, research or service/clinical interests. The decision was based on the outstanding accomplishments of the GRHD faculty. Congratulations, GRHD!
Apr 08, 2016:
TechOhio (the Ohio Development Services Agency) that showcases how the Ohio Third Frontier initiative is helping grow the state's technology economy has recently highlighted the research done by Red5 Pharmaceuticals LLC in a short video. Red5 Pharmaceuticals was co-founded by a GRHD member, Dr. Anthony Berdis, who is also serving as chief scientific officer of the company. Red5 Pharmaceuticals is developing new cancer treatment approaches and diagnostic kits. The company is working to expand its research to find new ways to treat breast, ovarian and pancreatic cancer. The company was previously awarded a $60,000 Technology Validation and Start-up Fund (TVSF) grant from Ohio Third Frontier. Congratulations, Tony!
Feb 26, 2016:
The National Heart, Lung, and Blood Institute (NIH) awards a grant in the total amount of $1.45 Million to Dr. Barsanjit Mazumder for his research on translational control of inflammation. Dr. Mazumder is holding his R01 grant since March 1, 2005 and renews it second time for the third consecutive term. The title of Dr. Mazumder’s grant is “Translational silencing in monocytes: role of L13a”. Dr. Mazumder’s research is devoted to the study of uncontrolled inflammation – a leading cause of many diseases such as atherosclerosis, colitis and/or cardiovascular disease. Dr. Mazumder is a recipient of the College of Science Outstanding Research Award (2006) and Distinguished Faculty Award for Research (2010) from Cleveland State University. Dr. Barsanjit Mazumder is one of the founding members of GRHD and a member of the GRHD planning committee. Congratulations, Barsan!
Feb 16, 2016:
Feb 04, 2016:
Dr. Anton Komar and the team of international researchers from the Max Planck Institute for Biophysical Chemistry, Goettingen and Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany published two high profile papers that appeared in the premier journals in the field, Molecular Cell and Science.
Dr. Komar and his colleagues studied the central principles of how proteins are produced by ribosomes in cells and how synonymous codon usage regulates translation elongation, co-translational folding, and protein quality in the cell. This work was supported by the International Human Frontiers Science Program (HFSP)
$900,000 grant awarded to Dr. Komar and his team. It contributes to our understanding of the origin of many human diseases caused by incorrect protein folding and gives a tool to upscale the production of functional proteins for medical and biotechnological purposes. HFSP
supports innovative, cutting edge research at the frontiers of the life sciences.
Feb 03, 2016:
GRHD faculty, Dr. Aimin Zhou, and his colleagues, Siu-Tung Yau, Professor, Department of Electrical Engineering and Computer Science, Harry Fox, Associate Professor, Department of Engineering Technology (both from the Washkewicz College of Engineering) and Eddie T. C. Lam, Associate Professor, Department of Health and Human Performance (College of Education and Human Services) received the Multi-College Interdisciplinary Research Program (MIRP) grant award totaling $75,000 for their project “An Ultrasensitive, Non-Invasive Detection Platform for Disease Biomarkers.”
The researcher of this team is focused on the development of a novel, ultrasensitive assay approach allowing for early detection of cancer and other diseases. The Multi-College Interdisciplinary Research Program provides funding for broad and collaborative research activities that are interdisciplinary and involve faculty from multiple colleges across CSU.
Jan 18, 2016:
Dec 22, 2015:
GRHD faculty member Dr. Valentin Boerner has received the award from Dr. John C. Vitullo’s Pilot and Bridge Funding Program to support his research on proteolytic activity of the proteasome in chromose pairing and break repair during meiosis. This research may help the development of innovative treatment of multiple myeloma, the second most common type of blood cancers. Congratulations, Valentin!
Dec 21, 2015:
The National Institutes of Health awards an AREA (R15) grant in the amount of $349,200 to Dr. Aaron Severson for his research on meiosis in model organism Caenorhabditis elegans. The title of the grant is "Specification of meiotic cohesin function by divergent alpha-kleisin subunits".
The proposed research will increase our understanding of the cellular machinery that forms normal sperm and eggs and reveal how defects in this machinery lead to infertility. Congratulations, Aaron!
Nov 16, 2015:
GRHD hosted a special seminar: "Multicolor flow cytometry on your bench top: guava easyCyte™ Flow Cytometry" presented by Yan Nikhamin, MS, MBA, EMD/Millipore Field Application Scientist. The guava easyCyte™ microcapillary flow cytometry systems are easy to use and offering both single sample and multi-sample processing.
Oct 30, 2015:
GRHD hosted the second GRHD – GRHD External Advisory Committee meeting. GRHD External Advisory Committee
includes 7 world renowned scientists, experts in various life sciences fields.
Oct 29, 2015:
A generous $150,000 bequest from Dr. George Stark, Ph.D., and his wife, Mary, will endow a graduate scholarship in GRHD. This gift is the largest to date pledged to GRHD. Dr. Stark earned a Ph.D. degree in Chemistry from Columbia University in 1959. After a postdoctoral fellowship at the Rockefeller University with Drs. William Stein and Stanford Moore (both received Nobel prize in Chemistry in 1972), he joined the Department of Biochemistry at Stanford University in 1963 (headed back at a time by another Nobel Laureate, Arthur Kornberg (Nobel Prize in Physiology or Medicine 1959)), becoming Professor in 1971. In 1983, he moved to the Imperial Cancer Research Fund in London as Associate Director of Research. In July 1992, he became the Chair of the Lerner Research Institute of The Cleveland Clinic Foundation, a position he held until August 2002. He is currently the Distinguished Scientist of the Lerner Research Institute, with a laboratory in the Department of Cancer Biology. Dr. Stark was elected to the National Academy of Sciences in 1986, to the Fellowship of the Royal Society in 1990 and to the Institute of Medicine in 2002. He has received the Sober, Milstein and Coley awards and was the Herbert Tabor lecturer at the 2011 annual meeting of the American Society for Biochemistry and Molecular Biology.
Dr. Stark has contributed to several different areas of modern biochemistry and molecular biology. Early work on enzyme mechanisms and protein chemistry led to the development of the Northern and Western techniques for analysis of specific RNAs and proteins. His laboratory has also studied gene amplification in mammalian cells, leading to an appreciation both of the mechanisms that generate amplified structures and the regulatory processes that prevent amplification from occurring in normal cells. A major project was to apply systematic genetic analysis to interferon-dependent signaling pathways. In collaboration with Dr. Ian Kerr, eight different mutant cell lines were isolated, each complemented by a cDNA encoding a different protein in the pathway. The work with interferon, together with that of Dr. James Darnell, led to the discovery of the family of JAK-STAT signaling pathways, which mediate responses to many different extracellular factors.
Mary Stark was trained in physics at the University of Michigan and has worked in the laboratory with George Stark for many years.
Oct 19, 2015:
DAPCEL, Inc donates $15,000 to support research at the Center for Gene Regulation in Health and Disease (GRHD). DAPCEL, Inc. is a research biotechnology company focused on the development of strategies for optimization of enhanced protein production in any desired host organism.
Oct 09, 2015:
Oct 05, 2015:
Oct 04, 2015:
Sept 25, 2015:
The National Science Foundation awarded $3,732,793 for a Northern Ohio collaborative research program.
Case Western Reserve University, Kent State University, the University of Akron, the University of Toledo, Youngstown State University, Bowling Green University and Cleveland State University will collaborate to create the Northern Ohio Alliance for Graduate Education and the Professoriate (NOA-AGEP): A Racially and Ethnically Inclusive Graduate Education Model in Biology, Chemistry and Engineering (BCE). Cleveland State University was awarded $239,975 within this program (Award No.: 1432864). Dr. Anton A. Komar, GRHD
director serves as a PI on the CSU's grant award. Prestigious ($21,000/year) scholarships are available for underrepresented minority (URM) students
, who wish to join CMMS collaborative doctoral programs in Regulatory Biology, Clinical - Bioanalytical Chemistry and Applied Biomedical Engineering in Fall 2016.
Sept 02, 2015:
Aug 05, 2015:
A volume in the highly popular and successful "Methods in Molecular Biology" series (a product of Humana Press/Springer) entitled "Macro-Glycoligands" and edited by Dr. Xue-Long Sun is scheduled for publication on November 14, 2015. The series was the first to introduce the step-by-step protocols approach that has become the standard in all biomedical protocol publishing. This volume details methods and protocols for the synthesis and characterization of glycopolymers and their biomedical applications.
June 25, 2015:
May 01, 2015:
Dr. Aaron Severson has been invited to chair a session at the 1st EMBO Workshop on structural maintenance of chromosomes (SMC) proteins - "SMC proteins: chromosomal organizers from bacteria to human" to be held in Vienna, Austria, May 12-15, 2015. Dr. Severson is the only junior faculty member chairing a session at this meeting. Congratulations, Aaron!
April 24, 2015:
Dr. Girish Shukla won College of Sciences and Health Professions Outstanding Research Award 2015. Congratulations, Girish! Four GRHD faculty received this award before, including: Dr. Barsanjit Mazumder (2006), Dr. Anton A. Komar (2008), Dr. Bibo Li (2009) and Dr. Xue-Long Sun (2010). In addition, Dr. Crystal M. Weyman was a recipient of the COSHP Outstanding Teaching Award 2007.
April 03, 2015:
Mahesheema Na, (PhD student in Dr. Kalafatis's lab) and Vallentinas Gruzdys (PhD student in Dr. Xue-Long Sun's lab) have been selected by the American Association for Clinical Chemistry (AACC) for the highly competitive SYCL (Society for Young Clinical Laboratorians) travel grant award to attend the 2015 AACC Annual Meeting in Atlanta, GA. Remarkably, CSU/GHRD/Clinical Chemistry students won 2 out of 3 SYCL grants awarded in 2015.
Congratulations, Sheema, Vallentinas, Dan and Drs. Kalafatis and Xue-Long Sun!
March 27, 2015:
March 04, 2015:
March 03, 2015:
An innovative approach for the combined diagnostics and treatment of cancer has been reported by Dr. Anthony J. Berdis and his colleagues in a recent publication in J. Biol. Chem, appeared on line on Feb 24, 2015. A metal-containing nucleoside designated Ir(III)-PPY nucleoside was shown to display both therapeutic and diagnostic properties against the human epidermal carcinoma cell line, KB3-1. Ir(III)-PPY nucleoside kills cancer cells by arresting cell cycle progression at G2/M. Fluorescent properties of the nucleoside at the same time allow quantitative measurements of the nucleoside uptake by cancer cells via monitoring the activity of a specific nucleoside transporter, hENT1. Nucleoside transporters are important players in optimizing the therapeutic response to chemotherapy and quantifying nucleoside transporter activity can help to predict therapeutic responses to nucleoside treatments. Congratulations, Tony!
For more than 100 years J. Biol. Chem. has been an essential resource for the international community of biomedical researchers.
Feb 27, 2015:
Dr. Xue-Long Sun's (and co-authors) article, entitled "Carbohydrate and Protein Immobilization onto Solid Surfaces by Sequential Diels-Alder and Azide-Alkyne Cycloadditions" that was published in Bioconjugate Chemistry (BC) in 2006, has been included in the special 25th Anniversary collection of the BC's best Articles and Communications. Congratulations, Xue-Long! Bioconjugate Chemistry publishes articles on all aspects of the joining of different molecular functions by chemical or biological means. This includes, among other topics, the conjugation of antibodies, nucleic acids, lipids, carbohydrates, or other biologically active molecules and their analogs with any molecular groups that add useful properties (drugs, radionuclides, toxins, fluorophores, photoprobes, inhibitors, enzymes, haptens, ligands, etc.).
Feb 13, 2015:
Congratulations to Dr. Anthony J. Berdis a member of GRHD and the Founder and Chief Scientific Officer of Red5 Pharmaceuticals LLC! Red5 Pharmaceuticals LLC has just received funding from the Ohio Third Frontier Foundation totaling $60,000 in the category Technology Validation and Start-up Fund for the research and development proposal, entitled “Diagnostic Kits to Predict Patient Response to Chemotherapy”. The goal of the Ohio Third Frontier Technology Validation and Start-up Fund (TVSF) is to create greater economic growth in Ohio based on start-up companies that commercialize technologies developed by Ohio institutions of higher education and other Ohio not-for-profit research institutions. Dr. Berdis is a recipient of the first-ever CSU Faculty Innovation Fund (FIF) award.
Feb 10, 2015:
Feb 5, 2015:
A groundbreaking study devoted to chromosome break repair mechanism has been published in the journal Molecular Cell by Dr. Valentin Boerner and his colleagues. Chromosomes store all our genetic information. The danger of losing genetic material makes chromosome breaks particularly hazardous. Not surprisingly, cells have powerful ways for repairing chromosome breaks. This response is orchestrated by master regulators called checkpoints. However, chromosome breaks are not always bad. During meiosis, cells gradually inflict a larger number of breaks on their chromosomes. These self-inflicted breaks are used to link maternal and paternal chromosomes and ensure their distribution in the meiosis cell division. A team led by Dr. Boerner has discovered a new, ultrasensitive checkpoint system that controls chromosome break repair, specifically, when there are only a few breaks per cell. Previously, it was assumed that two checkpoints called ATM and ATR perform overlapping functions during meiosis. The researchers now report (in a new study published online on Feb 5th) that only ATM activates chromosome break repair when break levels are low. The fact that cells monitor break numbers in such a specific way has wide implications. This study provides novel insights into how cells battle harmful genome damage. Furthermore, outside the germ line, ATM and ATR are important guardians against cancer and this study may have wide implications for radiation therapy and cancer treatment. Congratulations, Valentin!
is a companion to Cell
, the leading journal of biology and the highest-impact journal in the world.
Jan 25, 2015:
Dr. Xue-Long Sun's (and co-authors) article, entitled "Chemoenzymatic Bio-orthogonal Chemistry for Site-Specific Double Modification of Recombinant Thrombomodulin", that was published in ChemBioChem in 2013, was one of the 25 most accessed articles in ChemBioChem over the last 12 months. Congratulations, Xue-Long! ChemBioChem is a source for important primary and secondary information across the whole field of chemical biology, bio(in)organic chemistry, and biochemistry. Its mission is to integrate this wide and flourishing field, ranging from complex carbohydrates through peptides/proteins to DNA/RNA, from combinatorial chemistry and biology to signal transduction, from catalytic antibodies to protein folding, from bioinformatics and structural biology to drug design...
Oct 21, 2014:
Crain’s Cleveland Business - the leading source of business news in Northeast Ohio has highlighted a recent NIH grant received by Dr. Sailen Barik.
Oct 06, 2014:
Sept 30, 2014:
GRHD faculty member Dr. Xue-Long Sun has been elected a Fellow of the American Heart Association (FAHA) conferred by the Council on Basic Cardiovascular Sciences (BCVS). Fellowship is open to physicians, scientists, nurses and other healthcare professionals with a major and productive interest in cardiovascular diseases and stroke. Congratulations, Xue-Long!
Sept 19, 2014:
GRHD hosted the first GRHD – GRHD External Advisory Committee meeting. GRHD External Advisory Committee includes 7 world renowned scientists, experts in various life sciences fields. Follow the link http://www.csuohio.edu/grhd/external-advisory-committee to learn more about GRHD External Advisory committee.
Sept 16, 2014:
Congratulations to Dr. Sailen Barik for receiving a three-year R15 NIH grant award totaling $436,500. The grant is entitled "Structure and function of RNA viral interferon suppressor complexes". The long-term goal of this project is to decipher how RNA viruses suppress the host's innate immune response. The short-term goal is to glean a biochemical and mechanistic understanding how the two unique nonstructural (NS) proteins of respiratory syncytial virus (RSV) operate to suppress both the induction and function of type I interferon (IFN), which enables the virus to cause severe lower respiratory tract infection and associated mortality.
Aug 18, 2014:
Aug 1, 2014:
Dr. Anton A. Komar has received a three-year R15 NIH grant award totaling $436,500. The grant is entitled "Understanding the impact of disease causing mutations in FIX" and will further help Dr. Komar to enhance his work on understanding the molecular mechanisms behind several disease causing synonymous mutations leading to Hemophilia B.
July 2, 2014:
Dr. Aaron Severson has been selected to present a talk at the prestigious Gordon Research Conference on Genomic Instability and “Mechanisms That Cause DNA Damage and Related Diseases” to be held in Hong Kong, China, July 6-11, 2014. The title of his talk "Establishing and Releasing Cohesion During Meiosis". Congratulations, Aaron!
The Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies. For over 75 years, GRC's high-quality, cost-effective meetings have been recognized as the world's premier scientific conferences, where leading investigators from around the globe discuss their latest work and future challenges in a uniquely informal, interactive format.
June 5, 2014:
Congratulations to Dr. Anthony J. Berdis a member of GRHD and the Founder and Chief Scientific Officer of Red5 Pharmaceuticals LLC. Red5 Pharmaceuticals LLC has just received Northeast Ohio’s Innovation Fund Award totaling $25,000 that will help Dr. Berdis to develop novel diagnostic assays enabling a personalized medicine approach to chemotherapy of cancer patients. The Innovation Fund supports early-stage technology-based startups. On June 3, 2014 it has announced (in its latest funding round) five awards totaling $275,000. Three companies received $25,000 awards aimed at validating technologies and two received $100,000 awards meant to prove out business concepts.
May 28, 2014:
Congratulations to Dr. Xue-Long Sun, for winning a 2-year American Heart Association (AHA) Grant-in-Aid award for his proposal “Recombinant Thrombomodulin Glycoconjugate and Its Antithrombotic Activity.” Dr. Sun is an expert in glyco-affinity ligand engineering and targeted drug delivery applications. Dr. Sun is a member of GRHD faculty since 2009. He joined CSU in 2006 after completing his training at Emory University School of Medicine.
May 15, 2014:
Congratulations to Dr. Valentin Börner, for winning the Faculty Research and Development (FRD) award for his proposal "Role of the proteasome in chromosome stability."
Dr. Börner is a member of GRHD faculty since GRHD inception in 2008. He joined CSU in 2005 after completing post-doctoral training at Harvard University.
May 5, 2014:
GRHD receives donations from Fisher Scientific and its vendors to support GRHD Graduate Progress Report Seminar Series. We thank Christina Camuendo (Fisher Sci), Charlie Fink (Fisher Safety), Tricia Tortoreti (Thermo Sci Lab Equipment), Kholiswa Laird (Thermo Sci Manual Liquid Handling), Scott Wisniewski (Thermo Sci Nalge Nunc), Bob Myers (Thermo Sci Chromagraphy Consumables), Joshua Schaefer (Mettler Toledo), Eric Tepe (Sartorius), Christopher Yarima (Millipore Water), Bikram Chakraborty (Biotek), Michael Hutsell (GE Healthcare) for their support.
April 30, 2014:
April 15, 2014:
Congratulations to Dr. Michael Kalafatis, who recently received a three-year unrestricted grant from the Parker Foundation in the amount of $1.2 million to support his innovative research on cancer therapy. Dr. Kalafatis is a co-founding member of GRHD and member of the GRHD planning committee.
April 15, 2014:
Congratulations to Dr. Andrew Resnick, for wining the second Faculty Innovation Fund (FIF) award for his proposal, "Microperfusion Tissue Interrogator: platform technology development."
Dr. Resnick joined GRHD faculty in 2011. He is currently the only GRHD faculty representing Department of Physics at CSU.
April 3, 2014:
A pledge of $50,000 was made by Dr. John C. Vitullo to support pilot and innovative research projects at the Center for Gene Regulation in Health and Disease (GRHD). Dr. Vitullo was the COSHP college's 2013 Distinguished Alumni Award recipient. He holds a master's degree from Youngstown State University and a Ph.D. (1984) in Regulatory Biology from Cleveland State University. He is chief executive officer and co-founder of Omega Laboratories, Inc., one of only a few hair drug-testing laboratories in the world.
March 17, 2014:
Congratulations to Dr. Girish Shukla, who recently received notification of funding from the Department of Defense (DoD) for two grant proposals for his research on prostate cancer. Dr. Shukla's grants are Exploration - Hypothesis Development Awards from the DoD's Prostate Cancer Research Program. In addition to Dr. Shukla, these grants were awarded to faculty from distinguished research universities, including Stanford University, UCLA, and George Washington University. Furthermore, CSU was the only university with two funded awards.
January 31, 2014:
Congratulation to Dr. Anthony Berdis, who has earned the distinction of having received CSU’s first-ever Faculty Innovation Fund (FIF) award for his proposal “Diagnostic Kits to Quantify Pro-Mutagenic Replication in Hyperproliferative Diseases.” Dr. Berdis joined GRHD faculty in 2012. His research spans several fields ranging from chemistry to biochemistry and cancer pharmacology.
January 8, 2014:
Dr. Anton A. Komar has been appointed new director of the Center for Gene Regulation in Health and Disease (GRHD).
Dr. Komar joined the CSU faculty in 2005. He is a co-founding member of GRHD.
June 15, 2013:
Two Ph.D. students of GRHD member Dr. Michael Kalafatis presented their recent discoveries on the blood coagulation Factor V in major national and international conferences.
Joesph R. Wiencek has been selected by the American Association for Clinical Chemistry for the highly competitive $2,500 travel award to attend the 2013 AACC Annual Meeting in Houston, TX. Joe's work has also been selected for an oral presentation at the XXIV Congress of the International Society on Thrombosis and Haemostasis, in Amsterdam, the Netherlands from June 29 to July 4, 2013. Joe has also another eposter presentation at the same meeting. Mahesheema Na, another PhD student in Dr. Kalafatis' group, is also presenting two studies in the same meeting: one oral presentation and an eposter
. These studies offer important insights into the function of Factor V, deficiency in which leads to predisposition for hemorrhage, while some mutations (notably, Factor V Leiden) predispose for thrombosis. Our congratulations to Joe, Sheema and Dr. Kalafatis.
June 3, 2013:
Sujata Jha, a PhD student of Dr. Anton A. Komar, has been selected for oral presentation of her research at the EMBO conference, 'The Biology of Molecular Chaperones', 17 – 22 May 2013, Santa Margherita di Pula, Italy.
Our congratulations to Sujata, and to Dr. Komar! The Conference home page is here: http://events.embo.org/13-chaperone
May 29, 2013:
Congratulations to GRHD member Dr. Anton A. Komar for winning a 2-year American Heart Association Grant-in-Aid award on "Comparative study of nonsynonymous and synonymous mutations causing hemophilia B".
Dr. Komar is a renowned expert in multiple aspects of translational regulation, including co-translational protein folding and single nucleotide polymorphisms (SNPs).
Janunary 28 2013:
Congratulations to GRHD member Dr. Bin Su for receiving an NIH AREA award (R15) titled "Drug development of orally active anti-trypanosomiasis agents".
Dr. Su is a medicinal chemist focusing on anti-cancer and anti-parasite drug development. African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease caused by Trypanosoma brucei. It threatens over 60 million people in 36 countries of sub-Saharan Africa. There are no effective vaccines and satisfactory drugs for its treatment. Dr. Su and T. brucei biologist Dr. Bibo Li will work together to develop new small molecule drugs to treat this neglected disease.
November 21, 2012:
Congratulations to GRHD members for recently receiving a Federal grant (NIH/NCRR) titled "Nikon A1RSI Confocal Microscope" (PI: Dr. Sailen Barik; Major Users: Drs. Bibo Li, Barsanjit Mazumder, Xue-Long Sun, Roman Kondratov).
This high-power microscope, capable of capturing still and video images in fully programmed mode, will allow studies of cellular structures and their behavior in great detail and clarity.
September 23, 2011:
Dr. Roman Kondratov's funding success and his breakthrough research have been featured in Crain's Cleveland Business
The Cleveland State researcher won a $1.5 million grant to study the aging process. Dr. Kondratov will examine the effects of circadian clocks on aging under dietary restriction. Circadian rhythms are 24-hour internal cycles found in many living organisms. Read more
September 19, 2011:
Congratulations to GRHD member Dr. Valentin Boerner for winning a three-year R15 Federal grant (NIH) to study "Control of pairing and recombination during meiosis".
Dr. Boerner is an expert in the mechanism of chromosome segregation during gamete formation, a key factor for reproductive health in humans.
September 15, 2011:
Congratulations to GRHD member Dr. Roman Kondratov for winning a $1.4 million 5-year Federal (NIH) R01 grant to study "Circadian clock and dietary restriction".
Dietary restriction is powerful intervention that delays the development of age-associated pathologies and increases lifespan in many organisms including humans. Dr. Kondratov's laboratory studies the molecular mechanisms of dietary restriction and its interaction with the circadian clock.
September 14, 2011:
Congratulations to our newest GRHD member, Dr. Andrew Resnick, for receiving an NIH AREA award (R15) titled "Fluid flow may be an environmental modifier of ADPKD disease progression".
Research in his project will shed light on the autosomal dominant Polycystic Kidney Disease, which affects 1 in 1000 Americans, and for which no cure currently exists (http://kidney.niddk.nih.gov/kudiseases/pubs/polycystic/).
August 24, 2011:
Congratulations to GRHD member Dr. Aimin Zhou for winning a two-year R15 Federal grant (NIH) to study "The role of RNase L in the pathogenesis of inflammatory bowel diseases".
Dr. Zhou is an expert in RNase L, an important player in our body's defence against viruses, inflammation, and cancer. In the recent past, three other GRHD members, Drs. Mazumder, Sun and Li, also won large NIH grants
. Together, these highly competitive awards recognize and consolidate GRHD's overall mission to understand and cure human ailments through modern biomedical research.
February 16, 2011:
Congratulations to GRHD member Dr. Bibo Li, recent recipient of a major NIH grant!
Kudos and congratulations to our GRHD member, Dr. Bibo Li, for recently receiving a five-year NIH award totaling $1.8 million to continue her groundbreaking studies to understand how the Trypanosome parasite changes its surface proteins, which allows it to evade human immunity and cause African Trypanosomiasis, a fatal disease if left untreated. Dr. Li's success in this highly competitive field reflects the outstanding quality of research at GRHD. Of note, the 12 GRHD scientists, including Dr. Li, have collectively attracted roughly $11 million of external funding from various sources since 2000 to support cutting-edge biomedical research.
October 25, 2010:
October 8, 2008: